Rosa Canete-Yoham
Acute Care · Miami, FLNPI 1831587286
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 352 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by GSK at 26.8% of the total. 2025 is the largest year on record at $3,590, 2.8 times the $1,277 reported in 2021. Among acute care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 352 payments — averaging $25.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$716
- United Therapeutics Corporation$636
- Actelion Pharmaceuticals US, Inc.$603
- Boehringer Ingelheim$520
- Insmed, Inc.$441
- plus $4K from 26 others
What the payments were for
- Food & beverage$9,071100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 71 | $2,435 |
| AstraZeneca | 29 | $716 |
| United Therapeutics Corporation | 23 | $636 |
| Actelion Pharmaceuticals US, Inc. | 27 | $603 |
| Boehringer Ingelheim | 21 | $520 |
| Insmed, Inc. | 23 | $441 |
| Baxter Healthcare | 19 | $431 |
| Sanofi | 17 | $425 |
| Electromed, Inc. | 19 | $420 |
| Mallinckrodt Hospital Products Inc. | 13 | $348 |
| Regeneron Healthcare Solutions, Inc. | 15 | $293 |
| Merck | 10 | $287 |
| ANI Pharmaceuticals, Inc. | 9 | $270 |
| Mylan Specialty L.p. | 8 | $212 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $207 |
| Amgen | 8 | $159 |
| Verona Pharma, Inc. | 7 | $150 |
| Lilly USA, LLC | 4 | $64 |
| Optinose US, Inc. | 3 | $57 |
| Philips North America LLC | 3 | $57 |
| Viatris Specialty LLC | 2 | $51 |
| Resmed Corp | 2 | $40 |
| Novartis | 2 | $39 |
| Medtronic | 1 | $33 |
| Inogen, Inc. | 1 | $32 |
| Caris MPI, Inc. | 1 | $25 |
| Pfizer | 1 | $24 |
| Fisher & Paykel Healthcare Inc | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Bayer | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$734
- TRELEGY ELLIPTA$244
- DUPIXENT$239
- BREZTRI$133
How this compares
$9,077 in reported general payments places this provider in the 95th percentile of 1,150 acute care providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 210 | $139,324 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 86 | $57,351 |
| Breo ElliptaFluticasone/Vilanterol | 112 | $47,276 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $15,300 |
| SymbicortBudesonide/Formoterol Fumarate | 51 | $12,090 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $11,447 |
| Spiriva RespimatTiotropium Bromide | 16 | $9,324 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $7,824 |
| Arnuity ElliptaFluticasone Furoate | 14 | $3,137 |
| Azelastine Hcl | 104 | $2,988 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 117 | $1,916 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 17 | $861 |
| Ipratropium Bromide | 22 | $513 |
| Methylprednisolone | 69 | $512 |
| Azithromycin | 156 | $487 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $2,435 | $212,861385 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $716 | $69,441137 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $520 | $20,77140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,150 acute care providers in Florida.
Other acute care in Miami
- Yvette NaranjoMiami$12K
- Yuri CarmonaMiami$10K
- Monica RamirezMiami$9K
- Julio AcostaMiami$9K
- Uday DasariMiami$7K
- Julissa WilliamsMiami$7K
- Michelle ViteriMiami$6K
- Marie RenoitMiami$6K
- Rebecca JuliaoMiami$5K
- Lissette Gomez-RiosMiami$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.